MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies

By JPN, Pharmaceutical, USA

MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies .
The collaboration will launch multiple phase 1 and 2 clinical trials conducted by MD Anderson with the aim of expediting delivery of new therapies. The studies will incorporate translational work, including exploration of novel biomarkers as well as pre-clinical studies of new agents aimed at mechanisms of resistance to existing treatments. Media & Investors – Daiichi Sankyo

http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006721.html

More from tokioX :

  1. COVID-19: AstraZeneca supplies corona vaccine to Japan: Daiichi Sankyo, Meiji Seika Pharma
  2. 💊Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
  3. Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
  4. Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
  5. 第一三共、経皮吸収癌疼痛治療剤 フェンタニルクエン酸塩貼付剤 後発医薬品の商業化に向け協業
  6. 第一三共、バイスペシフィック抗体に関するZymeworks社との共同研究の進捗について
  7. Max Planck研究所とのがん領域における研究開発提携について − 第一三共  ( Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration )